A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis on a Stable Background of Methotrexate.
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2014
At a glance
- Drugs Fezakinumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Wyeth Pharmaceuticals
- 11 Apr 2011 Planned end date changed from 1 Feb 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 12 Oct 2010 Planned end date changed from Dec 2010 to Feb 2011 as reported by ClinicalTrials.gov.
- 09 Jan 2010 Additional locations identified as reported by ClinicalTrials.gov.